USANA Health Sciences, Inc.
NYSE:USNAPackaged Foods
+$0.71 today
- Market cap
- $244.42M
- Beta
- 0.77
- P/E (TTM)
- 39.6
- EPS (TTM)
- $0.48
Volume 0.15M
Average 0.12M
USNA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
USANA Health Sciences, Inc.NYSE: USNA
EBITDA · Q1 FY2026 · quarter ended Apr 2026
EBITDA declines year over year
Q1 FY2026 EBITDA of $25.49M fell 6.9% year over year, ahead of the -14.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 74.8% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.
Context
- EBITDA amounted to 8.9% of revenue in FY2025, down 2.7 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $47.44M (-42.2%) for the fiscal year ending Jan 2027, a slowdown from the -17.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- $25.49M+74.8% QoQ
- Last fiscal yearJan 2026
- $82.07M-17.0% YoY
- LTMApr 2026
- $80.17M-14.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -6.9% | -32.9% | -26.0 pp |
| 1 year | -17.0% | -42.2% | -25.2 pp |
| 3-year CAGR | -14.3% | -7.0% | +7.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 82.07M USD
- Year-over-year change
- -17.0%
- 4-year CAGR
- -19.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-03 | 82.07M | -17.0% |
| FY2024 | 2024-12-28 | 98.86M | -19.7% |
| FY2023 | 2023-12-31 | 123.11M | -5.5% |
| FY2022 | 2022-12-31 | 130.22M | -32.5% |
| FY2021 | 2021-12-31 | 192.89M | — |
EBITDA vs competitors
How USNA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.7% is the 5th highest of 8, against a peer median of +31.8%.
- EBITDA amounts to 8.7% of revenue for USNA, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥173.91M CNY | -62.8% | — | 0.9% | |
| LTM Apr 2026 | $130.53M USD | +484.5% | -2.1% | 7.2% | |
| LTM Mar 2026 | R$108.87M BRL | -84.2% | -71.6% | 20.0% | |
| LTM Apr 2026 | $80.17M USD | -14.7% | -14.3% | 8.7% | |
WESTWestrock Coffee Company, LLC | LTM Mar 2026 | $40.78M USD | +669.2% | +64.5% | 3.2% |
| LTM Mar 2026 | $25.07M USD | +31.8% | +67.2% | 10.9% | |
| LTM Apr 2026 | $14M USD | +68.1% | +47.5% | 7.4% | |
| LTM Mar 2026 | -$6.06M USD | -656.1% | — | 1.5% | |
| Peer median (excluding USNA) | — | +31.8% | +47.5% | 7.2% | |
Competitors are the stored peer set for USNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.19B | 998.6M | 921.01M | 854.5M | 925.26M |
| Cost of Revenue | 230.93M | 207.28M | 189.4M | 175.75M | 200.85M |
| Gross Profit | 955.53M | 791.32M | 731.62M | 678.75M | 724.41M |
| Gross Margin | 80.5% | 79.2% | 79.4% | 79.4% | 78.3% |
| Research & Development | 11.11M | 11.56M | 11.45M | 11.57M | 0 |
| Selling, General & Admin | 774.23M | 672.14M | 627.1M | 600.86M | 337.37M |
| Operating Expenses | 785.34M | 683.7M | 638.54M | 612.43M | 673.54M |
| Depreciation & Amortization | 22.19M | 21.41M | 20.4M | 22.23M | 39.7M |
| EBITDA | 192.89M | 130.22M | 123.11M | 98.86M | 82.07M |
| EBITDA Margin | 16.3% | 13.0% | 13.4% | 11.6% | 8.9% |
| Operating Income | 170.19M | 107.61M | 93.07M | 66.32M | 50.86M |
| Operating Margin | 14.3% | 10.8% | 10.1% | 7.8% | 5.5% |
| Interest Income | 2.52M | 3.79M | 9.64M | 11.32M | 2.42M |
| Interest Expense | 57K | 192K | 262K | 281K | 842K |
| Other Income / Expenses | 450K | 1.01M | 9.38M | 10.03M | (9.34M) |
| Income Before Tax | 170.64M | 108.62M | 102.45M | 76.35M | 41.53M |
| Pre-Tax Margin | 14.4% | 10.9% | 11.1% | 8.9% | 4.5% |
| Income Tax Expense | 54.14M | 39.27M | 38.67M | 34.29M | 30.05M |
| Net Income | 116.51M | 69.35M | 63.79M | 42.03M | 10.76M |
| Net Margin | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% |
| EPS (Basic) | 5.78 | 3.60 | 3.33 | 2.20 | 0.58 |
| EPS (Diluted) | 5.73 | 3.59 | 3.30 | 2.19 | 0.58 |
| Weighted Avg Shares | 20.15M | 19.25M | 19.25M | 19.06M | 18.57M |
| Weighted Avg Shares (Diluted) | 20.34M | 19.31M | 19.35M | 19.16M | 18.57M |
USANA Health Sciences, Inc.
NYSE:USNA
Intrinsic Alpha fair value
Locked
Current Price
$13.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.